MAP2K1 and cancer: Interestingly, data from the Genomics of Drug Sensitivity in Cancer (GDSC) initiative [28] indicate that APC mutations confer increased sensitivity to the MAPK pathway MEK1/2 inhibitor PD-0325901 (www.cancerRxgene.org, release version 5.0).